Post by Scripps Research

The Calibr-Skaggs Institute for Innovative Medicines has been awarded up to $5.1 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of The National Institutes of Health (NIH) to develop a long-acting injectable (LAI) therapy for individuals co-infected with HIV and hepatitis B virus HBV. The new program aims to replace daily oral HBV treatment with a once-monthly—or even once-quarterly—injectable, helping address the adherence challenges associated with lifelong daily dosing. “Long-acting therapies have already transformed HIV care by helping improve treatment adherence, but people living with both HIV and HBV continue to face the challenge of maintaining daily HBV treatment,” says Anil Gupta, director of medicinal chemistry at Calibr-Skaggs and principal investigator on the new grant. “Our long-acting injectable platform was designed specifically for settings where extended drug delivery can make a meaningful difference,” adds Arnab Chatterjee, executive vice president of Calibr-Skaggs. More: https://ow.ly/7XbI50ZcpSZ